Daiichi Sankyo/Forest’s Hypertension Therapy Azor Gets FDA Nod
This article was originally published in The Pink Sheet Daily
Executive Summary
Azor will compete against Novartis’ recently approved Exforge.
You may also be interested in...
Payer Cost Strategies Weigh On CV Fixed-Dose Combinations
Fixed-dose combination drugs represent an attractive marketing prospect for drug makers given their relative low development cost and the opportunity they represent to extend a brand's lifecycle
Payer Cost Strategies Weigh On CV Fixed-Dose Combinations
Fixed-dose combination drugs represent an attractive marketing prospect for drug makers given their relative low development cost and the opportunity they represent to extend a brand's lifecycle
Vytorin, Zetia, Other Combos In Spotlight At ACC Conference
Highlights of the upcoming American College of Cardiology conference include ENHANCE data and updates on ACCOMPLISH and ONTARGET trials.